Lv62
2318 积分 2024-06-06 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
5天前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
5天前
已完结
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
25天前
已完结
Antibody–peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins
1个月前
已完结
Associations of general and central obesity with risk of premature mortality among Chinese adults: A nationwide prospective cohort study
1个月前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
2个月前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
2个月前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
2个月前
已完结
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
2个月前
已完结
Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?
3个月前
已完结
皖公网安备34019202002308
